VBI Looking To Market More Potent, Less Expensive Hepatitis B Vaccine

Sci-B-Vac was shown more effective at fewer doses than Engerix-B in a Phase III study. VBI Vaccines sees its hepatitis B vaccine hitting potential markets by 2021.

VBI Vaccines Inc. is hoping that the price point for its new hepatitis B vaccine, Sci-B-Vac, as well as a favorable outcome against GlaxoSmithKline PLC’s Engerix-B, will give the trivalent vaccine a leg up in the market. Sci-B-Vac showed non-inferiority overall, and superiority in key subgroups, in its first Phase III trial.

The company hopes to make its new hepatitis B vaccine, a standard protocol for medical personnel and their patients, among others. “The number one determinant of adoption is cost,” VBI CEO Jeff Baxter told Scrip

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anti-infective

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By 

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By 

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.